Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This immediate-release combination drug contains **hydrocodone** (a semi-synthetic opioid agonist for pain relief), **acetaminophen** (a non-opioid analgesic and antipyretic), and **promethazine** (a first-generation antihistamine with antiemetic, sedative, and anti-allergic properties). Hydrocodone acts as a mu-opioid receptor agonist to reduce pain perception, acetaminophen provides analgesia and fever reduction via central mechanisms, and promethazine, an H1 histamine receptor antagonist, reduces nausea (notably opioid-induced nausea/vomiting), provides additional mild sedation, and may reduce allergic responses. This combination (marketed as Hydexor) was developed specifically for the **short-term management of acute pain** that requires an opioid, particularly in patients prone to opioid-induced nausea and vomiting, with the goal of addressing both pain and opioid-related side effects[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocodone + acetaminophen + promethazine.